Clinical Trials at Indiana University Melvin and Bren Simon Comprehensive Cancer Center
As of August 2026, 24 paid clinical trials are recruiting at Indiana University Melvin and Bren Simon Comprehensive Cancer Center, located at Indiana University Melvin and Bren Simon Comprehensive Cancer Center, 535 Barnhill Dr, Indianapolis, IN 46202, phone (888) 600-4822 in Indianapolis, Indiana. Active studies at this site cover conditions such as Heart Failure, Obesity and Prostate Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
24 clinical trials at Indiana University Melvin and Bren Simon Comprehensive Cancer Center
·Clear filters·A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Letrozole in Uterine Leiomyosarcoma
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant
CD4CAR for CD4+ Leukemia and Lymphoma
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Evaluating Tolerability of ePUHRT With Brachytherapy Boost
ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
Common conditions studied in Indianapolis
- Heart Failure (15 active studies)
- Obesity (14 active studies)
- Prostate Cancer (11 active studies)
- Dementia (10 active studies)
- Multiple Myeloma (10 active studies)
- Acute Myeloid Leukemia (8 active studies)
Leading research sponsors in Indianapolis
- Indiana University
- National Cancer Institute (NCI)
- Eli Lilly and Company
- Children's Oncology Group
- Janssen Research & Development, LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in Indianapolis?
There are approximately 865 recruiting clinical trials in Indianapolis, Indiana listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Indianapolis pay participants?
Most recruiting trials in Indianapolis compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Indianapolis?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Indianapolis?
The most common conditions under active study in Indianapolis include Heart Failure (15), Obesity (14), Prostate Cancer (11), Dementia (10), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Indianapolis?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Indianapolis on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Indianapolis?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Indianapolis?
Recruiting research sites in Indianapolis include Indiana University, Riley Hospital for Children, Indiana University School of Medicine, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Indianapolis right now?
The largest active categories in Indianapolis are Cancer & tumors (223), Cardiovascular (65), Diabetes & metabolic (53). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Indiana University Melvin and Bren Simon Comprehensive Cancer Center?
Indiana University Melvin and Bren Simon Comprehensive Cancer Center is located at Indiana University Melvin and Bren Simon Comprehensive Cancer Center, 535 Barnhill Dr, Indianapolis, IN 46202. Use the Google Maps link in the intro above to get directions.
How do I contact Indiana University Melvin and Bren Simon Comprehensive Cancer Center?
You can reach Indiana University Melvin and Bren Simon Comprehensive Cancer Center by phone at (888) 600-4822. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.